Live oral Salmonella enterica serovar typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi a and S. Paratyphi B

Clinical and Vaccine Immunology

Volumn 21, Issue 3, 2014, Pages 427-434

  Wahid, Rezwanul ^a   Zafar, Shah J ^a   McArthur, Monica A ^a   Pasetti, Marcela F ^a   Levine, Myron M ^a   Sztein, Marcelo B ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CVD 909; IMMUNOGLOBULIN G; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL SURVIVAL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MALE; NONHUMAN; NORMAL HUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLA PARATYPHI; SALMONELLA PARATYPHI B; SINGLE DRUG DOSE; VACCINATION;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, BACTERIAL; CELL LINE; CELL SURVIVAL; CROSS REACTIONS; FEMALE; HUMANS; MACROPHAGES; MALE; OPSONIN PROTEINS; PHAGOCYTOSIS; SALMONELLA PARATYPHI A; SALMONELLA PARATYPHI B; SALMONELLA TYPHI; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84896761735     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00786-13     Document Type: Article

References (51)

1. Crump JA, Luby SP, Mintz ED. 2004. The global burden of typhoid fever. Bull. World Health Organ. 82:346-353. (Pubitemid 38715071)
2. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. 2002. Typhoid fever. N. Engl. J. Med. 347:1770-1782. http://dx.doi.org/10.1056/NEJMra020201. (Pubitemid 35375617)
3. Crump JA, Mintz ED. 2010. Global trends in typhoid and paratyphoid fever. Clin. Infect. Dis. 50:241-246. http://dx.doi.org/10.1086/649541.
4. Fangtham M, Wilde H. 2008. Emergence of Salmonella Paratyphi A as a major cause of enteric fever: need for early detection, preventive measures, and effective vaccines. J. Travel Med. 15:344-350. http://dx.doi.org/10.1111/j.1708- 8305.2008.00237.x.
5. Meltzer E, Schwartz E. 2010. Enteric fever: a travel medicine oriented view. Curr. Opin. Infect. Dis. 23:432-437. http://dx.doi.org/10.1097/QCO. 0b013e32833c7ca1.
6. Ochiai RL, Wang X, von Seidlein L, Yang J, Bhutta ZA, Bhattacharya SK, Agtini M, Deen JL, Wain J, Kim DR, Ali M, Acosta CJ, Jodar L, Clemens JD. 2005. Salmonella Paratyphi A rates, Asia. Emerg. Infect. Dis. 11:1764-1766. http://dx.doi.org/10.3201/eid1111.050168.
7. Parry CM, Threlfall EJ. 2008. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr. Opin. Infect. Dis. 21:531-538. http://dx.doi.org/10.1097/QCO.0b013e32830f453a.
8. Tacket CO, Levine MM. 2007. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin. Infect. Dis. 45(Suppl 1):S20 -S23. http://dx.doi.org/10.1086/518135.
9. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN. 2006. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24:116-123. http://dx.doi.org/10. 1016/j.vaccine.2005.08.008. (Pubitemid 41752998)
10. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC. 2001. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344:1263-1269. http://dx.doi.org/10.1056/NEJM200104263441701. (Pubitemid 32372960)
11. Holt KE, Thomson NR, Wain J, Langridge GC, Hasan R, Bhutta ZA, Quail MA, Norbertczak H, Walker D, Simmonds M, White B, Bason N, Mungall K, Dougan G, Parkhill J. 2009. Pseudogene accumulation in the evolutionary histories of Salmonella enterica serovars Paratyphi A and Typhi. BMC Genomics 10:36. http://dx.doi.org/10.1186/1471-2164-10-36.
12. McClelland M, Sanderson KE, Clifton SW, Latreille P, Porwollik S, Sabo A, Meyer R, Bieri T, Ozersky P, McLellan M, Harkins CR, Wang C, Nguyen C, Berghoff A, Elliott G, Kohlberg S, Strong C, Du F, Carter J, Kremizki C, Layman D, Leonard S, Sun H, Fulton L, Nash W, Miner T, Minx P, Delehaunty K, Fronick C, Magrini V, Nhan M, Warren W, Florea L, Spieth J, Wilson RK. 2004. Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nat. Genet. 36:1268-1274. http://dx.doi.org/10.1038/ng1470. (Pubitemid 39577934)
13. Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R. 1990. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 8:81-84. (Pubitemid 20112889)
14. Levine MM, Ferreccio C, Black RE, Lagos R, San MO, Blackwelder WC. 2007. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin. Infect. Dis. 45(Suppl 1):S24 -S28. http://dx.doi.org/10.1086/518141.
15. Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, Haryanto P, Suprijanto E, Witham ND, Hoffman SL. 1991. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338:1055-1059. http://dx.doi.org/10.1016/0140-6736(91)91910-M.
16. Gupta SK, Medalla F, Omondi MW, Whichard JM, Fields PI, Gerner-Smidt P, Patel NJ, Cooper KL, Chiller TM, Mintz ED. 2008. Laboratory-based surveillance of paratyphoid fever in the United States: travel and antimicrobial resistance. Clin. Infect. Dis. 46:1656-1663. http://dx.doi.org/10.1086/587894. (Pubitemid 351706761)
17. Sztein MB, Tanner MK, Polotsky Y, Orenstein JM, Levine MM. 1995. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 155:3987-3993.
18. Salerno-Goncalves R, Pasetti MF, Sztein MB. 2002. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J. Immunol. 169:2196-2203. (Pubitemid 34857688)
19. + T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA. J. Immunol. 170:2734-2741.
20. + T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J. Immunol. 173:5852-5862.
21. Salerno-Goncalves R, Wahid R, Sztein MB. 2005. Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires. Infect. Immun. 73:3521-3530. http://dx.doi.org/10.1128/IAI.73.6.3521-3530.2005. (Pubitemid 40745896)
22. Salerno-Goncalves R, Sztein MB. 2006. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol. 14:536-542. http://dx.doi.org/10.1016/j.tim.2006.10.004. (Pubitemid 44755485)
23. + cells in volunteers immunized with the Ty21a typhoid vaccine. Clin. Vaccine Immunol. 17:1305-1314. http://dx.doi.org/10.1128/CVI.00234-10.
24. Sztein MB, Wasserman SS, Tacket CO, Edelman R, Hone D, Lindberg AA, Levine MM. 1994. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 170:1508-1517. http://dx.doi.org/10.1093/infdis/170.6. 1508. (Pubitemid 24369911)
25. Sztein MB. 2007. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin. Infect. Dis. 45(Suppl 1):S15-S19. http://dx.doi.org/ 10.1086/518140. (Pubitemid 47036019)
26. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. 2007. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 25:1416-1425. http://dx.doi.org/10.1016/j.vaccine.2006.10.040. (Pubitemid 46091821)
27. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. 2008. Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue-homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol. 1:389-398. http://dx.doi.org/10.1038/mi.2008.30.
28. + T cells in volunteers following Ty21a typhoid immunization. PLoS One 7:e38408. http://dx.doi.org/10.1371/ journal.pone.0038408.
29. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. 2012. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin. Vaccine Immunol. 19:825-834. http://dx.doi.org/10.1128/CVI.00058-12.
30. Pakkanen SH, Kantele JM, Kantele A. 2012. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine 30:6047-6053. http://dx.doi.org/10.1016/j.vaccine.2012.07.051.
31. Tagliabue A, Villa L, De Magistris MT, Romano M, Silvestri S, Boraschi D, Nencioni L. 1986. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty21a vaccine. J. Immunol. 137:1504-1510. (Pubitemid 16014798)
32. Levine MM, Herrington D, Murphy JR, Morris JG, Losonsky G, Tall B, Lindberg AA, Svenson S, Baqar S, Edwards MF. 1987. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J. Clin. Invest. 79:888-902. http://dx.doi.org/10.1172/JCI112899. (Pubitemid 17050917)
33. Lindow JC, Fimlaid KA, Bunn JY, Kirkpatrick BD. 2011. Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi. Infect. Immun. 79:3188-3194. http://dx.doi.org/10.1128/IAI.05081-11.
34. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. 2000. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect. Immun. 68:4647-4652. http://dx.doi.org/10.1128/IAI.68.8.4647-4652.2000. (Pubitemid 30497736)
35. Eloe-Fadrosh EA, McArthur MA, Seekatz AM, Drabek EF, Rasko DA, Sztein MB, Fraser CM. 2013. Impact of oral typhoid vaccination on the human gut microbiota and correlations with S. Typhi-specific immunological responses. PLoS One 8:e62026. http://dx.doi.org/10.1371/journal.pone.0062026.
36. +IgD- S. Typhi-specific IgA and IgG B memory cells in humans. Clin. Immunol. 138:187-200. http://dx.doi.org/10.1016/j.clim.2010.11.006.
37. Ishibashi Y, Arai T. 1996. A possible mechanism for host-specific pathogenesis of Salmonella serovars. Microb. Pathog. 21:435-446. http://dx.doi.org/10.1006/mpat.1996.0074. (Pubitemid 26421828)
38. Forrest BD, LaBrooy JT, Beyer L, Dearlove CE, Shearman DJ. 1991. The human humoral immune response to Salmonella typhi Ty21a. J. Infect. Dis. 163:336-345. http://dx.doi.org/10.1093/infdis/163.2.336.
39. Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, Holdridge R, LaPointe C, Hamlet S, Chatfield SN. 2005. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J. Infect. Dis. 192:360 -366. http://dx.doi.org/10.1086/431605.
40. Kollaritsch H, Cryz SJ, Jr, Lang AB, Herzog C, Que JU, Wiedermann G. 2000. Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi ty21a live oral vaccines after primary immunization and reimmunization. Vaccine 18:3031-3039. http://dx.doi.org/10.1016/S0264-410X(00) 00101-8. (Pubitemid 30303808)
41. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. 2004. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J. Infect. Dis. 190:565-570. http://dx.doi.org/10.1086/421469. (Pubitemid 38982097)
42. Viret JF, Favre D, Wegmuller B, Herzog C, Que JU, Cryz SJ, Jr, Lang AB. 1999. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect. Immun. 67:3680-3685. (Pubitemid 29291550)
43. Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP, Edelman R, Perry J, Bedford P, Brown D, Chatfield S, Dougan G, Levine MM. 2000. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68:1196-1201. http://dx.doi.org/10.1128/IAI.68.3.1196-1201.2000. (Pubitemid 30108510)
44. Forrest BD, LaBrooy JT, Robinson P, Dearlove CE, Shearman DJ. 1991. Specific immune response in the human respiratory tract following oral immunization with live typhoid vaccine. Infect. Immun. 59:1206-1209.
45. Jack DL, Dodds AW, Anwar N, Ison CA, Law A, Frosch M, Turner MW, Klein NJ. 1998. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J. Immunol. 160:1346-1353. (Pubitemid 28093434)
46. Ochsenbein AF, Zinkernagel RM. 2000. Natural antibodies and complement link innate and acquired immunity. Immunol. Today 21:624-630. http://dx.doi.org/10.1016/S0167-5699(00)01754-0. (Pubitemid 32044019)
47. Daeron M. 1997. Fc receptor biology. Annu. Rev. Immunol. 15:203-234. http://dx.doi.org/10.1146/annurev.immunol.15.1.203. (Pubitemid 27169280)
48. Nimmerjahn F, Ravetch JV. 2007. Fc-receptors as regulators of immunity. Adv. Immunol. 96:179-204. http://dx.doi.org/10.1016/S0065-2776(07)96005-8. (Pubitemid 350018720)
49. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S. 1999. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371-380. http://dx.doi.org/10.1084/ jem.189.2.371. (Pubitemid 29063258)
50. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797. http://dx.doi.org/10.1038/ni.1923.
51. Germanier R, Furer E. 1975. Isolation and characterization of gale E mutant Ty21a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 141:553-558.